Uni­ver­si­ties de­cry Biden's plan for 'march-in' rights as dis­in­cen­tiviz­ing bio­phar­ma part­ner­ships

A group of non­prof­its rep­re­sent­ing ma­jor aca­d­e­m­ic in­sti­tu­tions and med­ical schools has come out against Pres­i­dent Joe Biden’s new frame­work to use “march-in” rights to re­duce the price of some med­i­cines de­vel­oped with fed­er­al funds.

Echo­ing com­ments from in­dus­try groups like PhRMA, the as­so­ci­a­tions and non­prof­its ar­gued that the frame­work from De­cem­ber in­creas­es un­cer­tain­ty around when march-in rights might be con­sid­ered, “which will have a detri­men­tal and desta­bi­liz­ing ef­fect on uni­ver­si­ty and med­ical school tech­nol­o­gy trans­fer ef­forts and plan­ning.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER